Brief: Mesoblast Says U.S. FDA Accepts Co's BLA Resubmission For Remestemcel
08/03/2023 01:30
March 8 (Reuters) - Mesoblast Ltd MSB.AX :
* U.S. FDA ACCEPTS MESOBLAST'S BLA RESUBMISSION FOR
REMESTEMCEL
* ACCEPTANCE FOR REMESTEMCEL-L IN TREATMENT OF CHILDREN WITH
STEROID-REFRACTORY ACUTE GRAFT VERSUS HOST DISEASE
Source text for Eikon: ID:nASX99JSR1
Further company coverage: MSB.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Mesoblast
See all newsBrief: Mesoblast Reports QTRLY Ryoncil Net Revenues Of $30.3 Million
ASX-shares of Mesoblast rise after back-treatment drug hits patent target
Australia's Mesoblast soars on bagging licence for Mayo Clinic-developed tech
Brief: Mesoblast Acquires CAR Platform For Precision-Enhanced Cell Products
Brief: Mesoblast Says Ryoncil's Net Revenue For Quarter Increases To US$30.3M